Please login to the form below

Not currently logged in
Email:
Password:

Xultophy

This page shows the latest Xultophy news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk preps for speedy oral GLP-1 drug filing

Novo Nordisk preps for speedy oral GLP-1 drug filing

10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a combination insulin/GLP-1 shot which more than doubled to 1.6bn krone.

Latest news

More from news
Approximately 13 fully matching, plus 15 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics